Custom mRNA vaccine trial opens for advanced cancer patients
NCT ID NCT07182435
Summary
This early study is testing a personalized mRNA vaccine called RH125 for people with advanced solid tumors who have run out of standard treatment options. Researchers will give the vaccine alone or combined with a PD-1 blocker drug to 36 patients to check if it's safe and to see if it triggers an immune response against the cancer. The main goal is to find the right dose and understand side effects before testing if the treatment actually helps shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, Guangdong, 518100, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.